204 related articles for article (PubMed ID: 33562724)
21. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
22. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
Camara-Quintana JQ; Nitta RT; Li G
Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
[TBL] [Abstract][Full Text] [Related]
23. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
[TBL] [Abstract][Full Text] [Related]
24. The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
Chen WJ; Zhang X; Han H; Lv JN; Kang EM; Zhang YL; Liu WP; He XS; Wang J; Wang GH; Yu YB; Zhang W
Cell Death Dis; 2020 Aug; 11(8):668. PubMed ID: 32820151
[TBL] [Abstract][Full Text] [Related]
25. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
[TBL] [Abstract][Full Text] [Related]
26. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
Weise LM; Harter PN; Eibach S; Braczynski AK; Dunst M; Rieger J; Bähr O; Hattingen E; Steinbach JP; Plate KH; Seifert V; Mittelbronn M
Stereotact Funct Neurosurg; 2014; 92(3):129-39. PubMed ID: 24776650
[TBL] [Abstract][Full Text] [Related]
27. Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
Dahlrot RH; Larsen P; Boldt HB; Kreutzfeldt MS; Hansen S; Hjelmborg JB; Kristensen BW
J Neuropathol Exp Neurol; 2019 Jul; 78(7):633-640. PubMed ID: 31058280
[TBL] [Abstract][Full Text] [Related]
28. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
30. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
32. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
33. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
34. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Massey SC; White H; Whitmire P; Doyle T; Johnston SK; Singleton KW; Jackson PR; Hawkins-Daarud A; Bendok BR; Porter AB; Vora S; Sarkaria JN; Hu LS; Mrugala MM; Swanson KR
PLoS One; 2020; 15(3):e0230492. PubMed ID: 32218600
[TBL] [Abstract][Full Text] [Related]
35. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
[TBL] [Abstract][Full Text] [Related]
36. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
37. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
[TBL] [Abstract][Full Text] [Related]
38. [Prognostic significance of invasion in glioblastoma].
Szivós L; Virga J; Hortobágyi T; Zahuczky G; Uray I; Jenei A; Bognár L; Árkosy P; Klekner Á
Ideggyogy Sz; 2020 Sep; 73(9-10):317-325. PubMed ID: 33035418
[TBL] [Abstract][Full Text] [Related]
39. MGMT hypermethylation and MDR system in glioblastoma cancer stem cells.
Caldera V; Mellai M; Annovazzi L; Monzeglio O; Piazzi A; Schiffer D
Cancer Genomics Proteomics; 2012; 9(4):171-8. PubMed ID: 22798502
[TBL] [Abstract][Full Text] [Related]
40. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
